An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT02293681
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
Phase 3
Completed
- Conditions
- PainOsteoarthritis
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT02289716
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02289703
A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-49122944, 5 milligram (mg)Drug: Placebo
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02280018
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT02277444
A Prospective Patient Registry of Patients Exposed to Bedaquiline
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT02274389
A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Moxifloxacin-matching placeboDrug: Ibrutinib-matching placebo
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT02271438
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02262728
A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02260700
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: JNJ-54861911, 10 milligram (mg)Drug: PlaceboDrug: JNJ-54861911, 50 mg
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 114
- Registration Number
- NCT02260674
© Copyright 2025. All Rights Reserved by MedPath